MATISSE

Mondial Assessment of Thromboembolism treatment Initiated by Synthetic pentasaccharide with Symptomatic Endpoints—Pulmonary Embolism. A clinical trial comparing the efficacy and safety of the antithrombotic agent fondaparinux to unfractionated heparin in the initial treatment of symptomatic pulmonary embolism
Conclusion Recurrent fatal or nonfatal pulmonary embolism and deep vein thrombosis in 3.8% of fondaparinux patients and in 5.0% of unfractionated heparin patients. Major bleeding occurred in 2.0% of fondaparinux patients vs. 2.4% of unfractionated heparin patients, but 5.2% mortality in fondaparinux group vs. 4.4% in unfractionated heparin group